Here’s what we know about availability, pricing, and more.

Cervical cancer: CC vaccine will be available in coming months

New Delhi [India]1 September, ANI: India’s first proprietary quadrivalent human papillomavirus (qHPV) vaccine becomes available at an affordable price, says Adar Poonawala, CEO, Serum Institute of India (SII) said on Thursday.

“A vaccine for cervical cancer will be available in the next few months. Prices will be announced in the next few months. The price could be Rs 200-400, but the price is yet to be determined. No. It will be finalized after manufacture and consultation with the Government of India,” Poonawala said.

Commonwealth Minister Dr Jitendra Singh, who was the guest of honor at the launch of India’s first indigenous vaccine for cervical cancer prevention, CERVAVAC, said: Cervical cancer is prevalent among women in younger age groups.Thanks to the Prime Minister, we can now afford to seek preventive care.This vaccine will be affordable.

On the launch of the vaccine, Singh congratulated Adar Poonawala, a team of scientists, saying, “The way they have come to this launch in their very passionate pursuit is for scientists and, as Poonawala said, It will be officially launched.” Several months. “

“As the minister said today, we started science and celebrated science. A vaccine for cervical cancer will be available in a few months. to and later to the world,” Poonawala said of Vaccines.

“We are preparing to manufacture 200 million doses in two years,” Poonawala said of the vaccine production.

The Federal Minister further added that this affordable and cost-effective vaccine would be a great success for the Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC) as India moves one step closer to Prime Minister Modi’s vision of Atmanirbhar Bharat. I said it was an important day.

“This is a historic milestone in preventive medicine under the leadership of Prime Minister Narendra Modi. India’s first independently developed quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer was approved by the Federal Ministry of Science and Technology’s Biotechnology It was initiated by the technology department,” Singh tweeted.

Labor Minister Singh said cervical cancer ranks as the second most common cancer in India and accounts for almost a quarter of all cervical cancer deaths globally, despite being largely preventable. I pointed out that it occupies 1.

Current estimates estimate that approximately 1.25 million women in India are diagnosed with cervical cancer each year, and more than 75,000 die from the disease, and HPV 16 accounts for 83% of invasive cervical cancers in India. Or 18, he said. 70% of cases worldwide.

‘CERVAVAC’ is the result of a partnership between DBT and BIRAC with the Bill & Melinda Gates Foundation supported by the Serum Institute of India Private Limited for the proprietary development of a quadrivalent vaccine through the partnership program ‘Grand Challenges India’.

Dr Rajesh Gokhale, secretary of DBT, said, “This is a celebration of the collective efforts of all stakeholders and partnerships with industry are extremely important to carry out the hugely funded research and development. He added that it has become important: India will break down all barriers for the betterment of mankind.”

Dr N Kalaiselvi, Director General of CSIR, said in his speech that cancer vaccines would greatly help women in India and around the world, and versions 1, 2 and 3 of ‘CERVAVAC’ could emerge in the near future. said. Short-lived.

“India can do it,” she said, adding that in true Atmanir Bharat spirit, she will come up with Indian solutions to India’s problems.

Renowned film actress Manisha Koirala, who bravely fought and emerged victorious against ovarian cancer, attended virtually to thank the Ministry of Science and Technology, especially DBT, for reaching this milestone.

“Today is a great day for women in India and around the world because there is life beyond cancer,” Koirala said.

A cost-effective preventative treatment would encourage millions of such patients to say “Yes to Life,” she said.

[SOURCE: ANI]